SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003416 to Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic, Inc.
Date: March 31, 2025 · CIK: 0001681087 · Accession: 0000000000-25-003416

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286133

Date
March 31, 2025
Author
Division of
Form
UPLOAD
Company
Tectonic Therapeutic, Inc.

Letter

Re: Tectonic Therapeutic, Inc. Registration Statement on Form S-1 Filed March 26, 2025 File No. 333-286133 Dear Daniel Lochner:

March 31, 2025

Daniel Lochner Chief Financial Officer Tectonic Therapeutic, Inc. 490 Arsenal Way Suite 210 Watertown, MA 02472

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brandon Fenn, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 31, 2025

Daniel Lochner
Chief Financial Officer
Tectonic Therapeutic, Inc.
490 Arsenal Way
Suite 210
Watertown, MA 02472

 Re: Tectonic Therapeutic, Inc.
 Registration Statement on Form S-1
 Filed March 26, 2025
 File No. 333-286133
Dear Daniel Lochner:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jessica Dickerson at 202-551-8013 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Brandon Fenn, Esq.
</TEXT>
</DOCUMENT>